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Background: Previous studies have suggested that NPM1 mutations may be a marker for
response to all-trans retinoic acid (ATRA) given as an adjunct to intensive chemotherapy in
older patients with acute myeloid leukemia (AML).
Patients and Methods: We examined the impact of the addition of ATRA among
patients with diploid cytogenetics treated on a randomized phase II study of fludara-
bine+ cytarabine+ idarubicine±G-CSF±ATRA with available data on their NPM1 muta-
tion status. Between September 1995 and November 1997, 215 patients were enrolled in
the study. Among them, 70 patients had diploid cytogenetic and are the subjects of this
analysis.
Results:The median age of the 70 patients was 66 years (range 23–87). Twenty (29%) of
patients had NPM1 mutations. Among them 7 (35%) did and 13 (65%) did not receive
ATRA in combination with chemotherapy. Complete remission (CR) was achieved in 71%
of patients treated with ATRA as compared to 69% without ATRA (P = 0.62). With median
follow-up of 12.5 years, the overall survival (OS), event-free survival (EFS), and relapse-free
survival (RFS) were similar among patients who received ATRA compared to no ATRA
regardless of NPM1 mutation status.
Conclusion: The addition of ATRA to intensive chemotherapy did not affect the overall
outcome of patients with AML regardless of NPM1 mutation status.
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INTRODUCTION
The addition of all-trans retinoic acid (ATRA) to chemotherapy
has changed the natural history of acute promyelocytic leukemia
(APL) by inducing terminal differentiation of the promyelocyte
into mature cells (1, 2). Preclinical data suggests that ATRA may
also sensitize non-APL leukemic blasts to cytarabine and anthra-
cyclines by downregulating bcl-2 and related proteins that inhibit
apoptosis (3–6). These observations provided a rationale for sev-
eral clinical trials to evaluate the impact of adding ATRA to con-
ventional chemotherapy in non-APL patients; however, the reports
of these trials have been conflicting. Venditti et al. first reported a
significantly higher complete remission (CR) rate when ATRA was
added to low dose cytarabine in 33 patients with poor risk AML
(7). However, several subsequent trials have failed to show a benefit
from adding ATRA to conventional chemotherapies (8–10).
Nucleophosmin (NPM1) gene mutations are among the most
common gene alteration in acute myeloid leukemia (AML) and
mainly occur in AML with normal karyotype (NK-AML) (11–
13). NPM1 plays an important role in cell growth, proliferation,
and terminal differentiation (14). The prognostic impact of NPM1
mutations is favorable among patients with NK-AML (12, 15).
However, the presence of concomitant fms-like tyrosine kinase 3
internal tandem duplication (FLT3-ITD) mutation will worsen the
outcome (16).
In a subgroup analysis of their AML HD98B randomized trial in
elderly patients with AML, Schlenk et al. showed a higher response
rate and better relapse-free survival (RFS) and overall survival
(OS) only in patients with NPM1 mutations without FLT3-ITD
(NPM+/FLT3−ITD−) who received ATRA as part of their induc-
tion regimen (17); however, a subgroup analysis of the MRC
AML12 trial failed to show a similar benefit in NPM+/FLT3−
patients (18).
Here we evaluate the impact of the addition of ATRA to
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10–19%) were enrolled in a phase II randomized clinical trial
of fludarabine, cytarabine, and Idarubicin±A TRA± granulocyte
colony-stimulating factor (G-CSF) (8). The trial design and results
have been reported previously (8). Patients were eligible to partic-
ipate if they had one of the following features: antecedent hemato-
logical disorder (AHD) defined as a history of an abnormal blood
count (hemoglobin,≤12 g/dL, or neutrophils≤1,500/µL, or white
blood cells (WBC) ≤10,000/µL, or platelet count ≤150,000/µL)
documented to be present for at least 1 month before their pre-
sentation to MD Anderson Cancer Center (MDACC), therapy-
related AML or MDS, high bilirubin (>2.9 mg/mL) or creati-
nine (>1.5 mg/mL). Patients were randomly assigned to receive
(1) fludarabine 30 mg/m2× days (1–4)+ cytarabine 2 g/m2 days
(1–4)+ idarubicin 12 mg/m2 days (2–4)= FAI, (2) FAI+G-CSF
(200 mg/m2 daily), (3) FAI+ATRA 45 mg/m2 in two divided
dose, or (4) FAI+ATRA+G-CSF as described previously (8).
All patients signed informed consent to participate in the trial
in accordance with the guidelines reported in the Declaration
of Helsinki. The study was approved by the Institutional Review
Board (IRB) at MDACC. Seventy patients with NK-AML who
participated in this study and had stored bone marrow biopsy
specimens were the subject of this analysis.
DETECTION OF NPM1 MUTATIONS
Bone marrow specimens were examined by immunohistochem-
istry (IHC) for the presence of cytoplasmic NPM1 (corresponding
to NPM1 mutations). To detect NPM1 mutations, exon 12 was
amplified by PCR using the following primers: GATGTTGAAC-
TATGCAAAGAGACA (forward) and AACCAAGCAAAGGGTG-
GAGTT (reverse). The PCR products were purified by MinE-
lute TM PCR purification Kit (QIAGEN, Valencia, CA, USA)
and directly sequenced using the GGCATTTTGGACAACACA
(reverse) primer (Sanger sequencing) using the fluorescence dye
chain-terminator chemistry method on ABI Prism 3700 DNA
Analyzer (Applied Biosystems, Foster City, CA, USA), and analyzed
by using the 310 Genetic Analyzer (Sanger sequencing; Applied
Biosystems).
Immunohistochemistry studies were performed using previ-
ously described methods (19). Routinely processed BM trephine
biopsy tissue sections were subjected to antigen retrieval and
immunostained with an anti-NPM1 monoclonal antibody, clone
376 (Dako, Carpinteria, CA, USA) using an alkaline phosphatase
monoclonal anti-alkaline phosphatase (APAAP) technique (20).
In addition, the BM tissue sections were stained in parallel with
a mouse monoclonal antibody directed against nucleolin (C23)
(Santa Cruz, Biotechnology, Santa Cruz, CA, USA), another nucle-
olar protein, which served as a nuclear staining control. In NPM1
mutated AML cases, NPM protein is abnormally localized in the
cytoplasm of most leukemic cells whereas nucleolin/C23 expres-
sion is restricted to the nucleus (19). In NPM1 unmutated cases,
NPM protein is restricted to the nucleus.
We found a complete concordance between the results obtained
by IHC and the results obtained by DNA sequencing of NPM1.
Only two cases showed discordance between results obtained by
IHC and DNA sequencing: nuclear NPM1 protein by IHC but
DNA sequencing showed NPM1 mutation.
DEFINITIONS OF OUTCOME
Complete remission was defined as less than 5% bone marrow
blasts, an absolute neutrophil count of 1.0× 109/L or more, a
platelet count of 100× 109/L or more, no blasts in the periph-
eral blood, and no extramedullary leukemia. Failures were defined
as either refractory disease or early death (death less than
7 days after completion of the first course of induction ther-
apy). Relapse was defined as more than 5% bone marrow blasts
unrelated to recovery from the preceding course of chemother-
apy or new extramedullary leukemia in patients with previously
documented CR.
Overall survival was measured from the time of randomization
to time of death or last follows up. Event-free survival (EFS) was
measured form the time of randomization to the date of an event,
defined as death, relapse, or failure to achieve CR due to resistant
disease. RFS was measured from the date of achievement of CR to
the date of death in CR, relapse, or at last follow-up.
Table 1 | Patient characteristics.
Characteristics No. (%) NPM1 mut. no. (%) NPM1 wt. no. (%) P value
No. 70 20 (29) 50 (71)
Median age, years (range) 66 (23–87) 64 (40–81) 67 (23–87) 0.58
≤60 23 (33) 7 (35) 16 (32) 0.20
>60 47 (67) 13 (75) 34 (68)
AHD 42 (60%) 11 (55) 31 (62) 0.16
Median WBC×109/L (range) 12.8 (0.3–245) 10.7 (0.5–245) 13.7 (0.3–196) 0.13
Median hemoglobin g/dL (range) 7.8 (2.9–12.5) 8.2 (6.9–12.5) 7.8 (2.9–12.2) 0.04
Median platelets×103/mL (range) 55 (8–334) 55 (12–275) 55 (8–334) 0.41
Median BM blasts % (range) 52 (11–94) 54 (13–91) 52 (11–94) 0.68
Treatment with ATRA 0.11
Yes 36 (51) 7 (35) 29 (58)
No 34 (49) 13 (65) 21 (42)
NPM1, nucleophosmin 1; wt, wild type; mut, mutated; AHD, antecedent hematologic disorder; WBC, white blood cell count; BM, bone marrow; ATRA, all-trans
retinoic acid.
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STATISTICAL ANALYSIS
Differences among variables were evaluated by the Fisher exact
test and Mann–WhitneyU test for categorical and numerical vari-
ables, respectively. Time-to-event analyses were performed by the
Kaplan–Meier method, and curves were compared with the two-
tailed log rank test. A two sided P value <0.05 was considered
to be statistically significant. All analyses were performed using
Statistica 10 software (StatSoft Inc., Tulsa, OK, USA).
RESULTS
PATIENT CHARACTERISTICS
Among the 70 patients with NK-AML who were included in this
analysis, 20 (29%) patients hadNPM1mutations. Patient’s charac-
teristics are summarized in Table 1. The median age for the entire
group was 66 (range, 23–87). Forty two (60%) had a history of
AHD. A total of 36 (51%) patients were treated with ATRA in com-
bination with chemotherapy. Patients with NPM1 mutations have
similar clinical characteristics compared to patients with wild type
NMP1 except hemoglobin levels which were lower in patients with
wild type NPM1 (P = 0.04). Among them, seven (35%) patients
received treatment with ATRA plus chemotherapy.
RESPONSE RATE
The CR rate for the entire group was 63%. Patients treated with
ATRA in combination with chemotherapy had similar response
rate to patients who did not receive ATRA (67 vs. 59%, respec-
tively, P = 0.14). The CR rate was similar for patients with and
without mutated NPM1 (70 vs. 60%, respectively, P = 0.43). CR
rate in patients with NPM1 mutations did no differ according
to whether they received ATRA or not (71 vs. 69%, respectively,
P = 0.62) (Table 2). Early induction mortality was also similar
among patients who received ATRA vs. no ATRA regardless of the
NPM1 mutations status (Table 2).
SURVIVAL ANALYSIS
With a median follow-up of 12.5 years, the median OS, EFS, and
RFS for the entire group were 11.5 months (range, 0.25–183.75),
7 months (range, 0.25–171), and 11.5 months (range, 0.25–170),
respectively. There were no differences in the OS, EFS, and RFS
among patients who treated with ATRA vs. No ATRA (Table 2;
Figure 1). More importantly, the addition of ATRA to induction
chemotherapy did not affect the OS, EFS, and RFS of patients with
mutated NPM1 (Table 2; Figure 2).
DISCUSSION
In this randomized clinical trial of fludarabine, cytarabine, and
Idarubicin±ATRA±G-CSF, the addition of ATRA to intensive
chemotherapy did not improve the outcome (CR, OS, EFS, and
RFS) of patients with non-APL AML (8). In addition, in subgroup
analysis, patients with diploid karyotype and mutated NPM1 did
not benefit from the addition of ATRA to their chemotherapy
and had similar outcome compared to patients with wild type
NPM1.
Several clinical trials have evaluated the impact of the addition
of ATRA to intensive chemotherapy in non-APL AML; however,
the results have not been consistent. Venditti et al. reported that
the combination of ATRA and low dose cytarabine was associ-
ated with a high CR rate in patients with poor risk AML who
Table 2 | Outcome by NPM1 mutations status and treatment with
ATRA.
Parameter NPM1 wt. NPM1 mut. P value
Total no. 50 20
ATRA 29 (58) 7 (35) 0.07
No ATRA 21 (42) 13 (65)
Response rate
ATRA 19 (66) 5 (71) 0.08
No ATRA 11 (52) 9 (69)
4 weeks mortality
ATRA 5 (17) 1 (14) 0.34
No ATRA 4 (18) 3 (23)
8 weeks mortality
ATRA 8 (28) 1 (14) 0.11
No ATRA 6 (28) 5 (38)
Median OS (weeks)
ATRA 52 (1–684) 41 (3–452) 0.78
No ATRA 41 (2–360) 60 (1–735)
Median EFS (weeks)
ATRA 30 (1–684) 34 (3–176) 0.18
No ATRA 18 (2–232) 31 (1–650)
Median RFS (weeks)
ATRA 41 (15–680) 82 (10–173) 0.21
No ATRA 37 (9–228) 56 (1–646)
NPM1, nucleophosmin;WT,wild type;mut, mutated; ATRA, all-trans retinoic acid;
OS, overall survival; EFS, event-free survival; RFS, relapse-free survival.
were unfit to receive intensive chemotherapy (7). However, several
subsequent trials have not confirmed this result (8–10). We pre-
viously reported a randomized phase II trial of ATRA in combi-
nation with fludarabine, cytarabine, and Idarubicin ±G-CSF and
found that the addition of ATRA did not impact the outcome
among patients with poor risk AML and high risk MDS (8). This
result was similar to three large randomized trials conducted by
the British Medical Research Council (MRC) in medically unfit
patients (MRC AML14) (10), newly diagnosed younger patients
(MRC AML12), and in relapsed refractory patients (MRC AML-
HR) (9). All of these trials failed to show any significant effect of
ATRA in non-APL AML.
In a subgroup analysis of a randomized trial conducted by the
German–Austrian AML Study Group (AMLSG), Schlenk et al.
showed that the addition of ATRA to intensive chemotherapy was
associated with a significant improvement in response rate, OS,
and EFS only in elderly patients who were NPM1+/FLT3−ITD−
(17). In contrast, subgroup analysis of MRC AML 12 trial
failed to show any benefit from the addition of ATRA to
intensive chemotherapy in general and specifically in patients
with NPM1 mutations with or without FLT3-ITD mutations in
terms of response rate (P = 0.6 and 0.1, respectively), relapse
(P = 0.8 and 0.2, respectively), and OS (P= 0.2 and 0.3, respec-
tively) (18).
The differences in the results of these trials may be related to
differences in the patient populations as well as the chemother-
apy regimens used in combination with ATRA. Furthermore, the

























































Nazha et al. ATRA with chemotherapy in NPM1 mutated AML
FIGURE 1 | Overall survival, event-free survival, and relapse-free survival (RFS) in patients who received ATRA vs. no ATRA. (A) Overall survival among
patients who received ATRA vs. no ATRA. (B) Event-free survival among patients who received ATRA vs. no ATRA. (C) RFS among patients who received ATRA
vs. no ATRA.
FIGURE 2 | Overall survival, event-free survival, and relapse-free survival
based on NPM1 mutations status and treatment with ATRA. (A) Overall
survival among patients with mutated vs. wild type NPM1 who received
ATRA vs. no ATRA. (B) Event-free survival among patients with mutated vs.
wild type NPM1 who received ATRA vs. no ATRA. (C) RFS among patients
with mutated vs. wild type NPM1 who received ATRA vs. no ATRA.
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dosing schedule of ATRA and whether it is administered before,
during, or after exposure to cytotoxic chemotherapies may be
important.
Although preclinical data suggests that ATRA may enhance
the apoptotic effect of drugs such as cytarabine and daunoru-
bicin through the suppression of bcl-2, the exact mechanisms
by which ATRA may affect leukemic myeloid cells with mutant
NPM1 is not fully understood. Preclinical studies have suggested
that ATRA may induce apoptosis in NPM1 mutated AML cell lines
by down-regulating NPM1 protein (20).
Limitations of this study include the small sample size of NPM1
mutated patients and that other mutations such as FLT3-ITD were
not analyzed in this retrospective study; however, the impact of
FLT3-ITD status on the response to ATRA in patients with mutated
NPM1 remains controversial (18).
In summary, the addition of ATRA to intensive chemother-
apy did not impact the overall outcome of patients with AML.
There was no significant difference in CR rate, EFS, or OS in
NPM1 mutated diploid AML receiving ATRA as an adjunct to
chemotherapy.
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